BioMimetic Therapeutics Receives First Orthopedic Marketing Approval For Augment™ Bone Graft

BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) announced today that it has received approval from Health Canada to begin the marketing of its lead orthopedic product, Augment™ Bone Graft, as an alternative to the use of autograft in midfoot, hindfoot and ankle fusion indications in Canada. “After rigorous pre-clinical and clinical evaluation of the product, BioMimetic is now ready to introduce this novel, implantable biologic to the marketplace,” commented Dr. Samuel E.

source : www.medicalnewstoday.com

Related News:

• Grandsons Can Inherit Grandpa’s Bone Weakness
• What Is Paget’s Disease Of Bone? What Causes Paget’s Disease?
• A Cupful of Health Benefits
• Calcium and vitamin D supplements reduce the risk of bone fractures in everyone, young and old
• New Gene Discovered For Recessive Form Of Brittle Bone Disease
• Agents Targeting Prostate Cancer Bone Metastasis
• Nanoscale Changes In Collagen Are A Tipoff To Bone Health
• Women At Higher Risk Of Significant Bone Loss On Injectable Birth Control Identified By UTMB Study
• Bone Strengthening Drugs Linked To Lower Breast ancer Incidence
• ASH: PTLD Responds to Immunosuppression utback

Details :
Submited at Thursday, November 5th, 2009 at 1:00 am on Orthopaedic by jessica
Comment RSS 2.0 - leave a comment - trackback